Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic diseases
currently in the context of obesity worldwide, which contains a spectrum of chronic liver …

Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut
microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with …

Background Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with a high
prevalence worldwide, seriously harming human health, and its pathogenesis remains …

BACKGROUND: The manipulation of gut microbiota via administration of probiotics has
been proposed as a potential strategy for the treatment of non-alcoholic fatty liver disease …

Abstract Background and Aim Several studies observed alterations in the gut microbiota in
patients with non‐alcoholic fatty liver disease (NAFLD). However, analyzed patient …

The interaction of gut microbiota, related metabolites and inflammation factors with
nonalcoholic fatty liver disease (NAFLD) remains unclearly defined. The aim of this …

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases involving
hepatic fat accumulation, inflammation with the potential progression to fibrosis and cirrhosis …

Non-alcoholic fatty liver disease (NAFLD) is an increasingly important cause of chronic liver
disease globally. Similar to metabolic syndrome and obesity, NAFLD is associated with …

Non-alcoholic fatty liver disease (NAFLD) is a significant global health burden in children,
adolescents and adults with substantial rise in prevalence over the last decades …

Results Probiotics, as biological factors, control the gut microbiota and result in its
progression. It is in this sense that they are suggestive of a new and a natural way of …